Pancreatic Cancer Research

ResearcherKurume UniversityActive in the last 2 years

Yoshiki Naito

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5292-2785; OpenAlex author ID A5062402333. Sources: OpenAlex.

Their work

Papers
13 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
56
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: none · 2014: 2 papers · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper

Papers 13

  1. Pancreatic Juice-Derived microRNA-4516 and microRNA-4674 as Novel Biomarkers for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.gastha.2024.04.011↗
  2. KRAS Mutation Analysis Using Cell-free DNA of Pancreatic Cancer. First author DOI 10.21873/anticanres.16434↗
  3. Concordance of the histological diagnosis of type 1 autoimmune pancreatitis and its distinction from pancreatic ductal adenocarcinoma with endoscopic ultrasoun… Co-author DOI 10.1007/s00428-021-03236-w↗
  4. Predictive and Prognostic Value of SUOX Expression in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.15913↗
  5. A deep learning model to detect pancreatic ductal adenocarcinoma on endoscopic ultrasound-guided fine-needle biopsy. Co-author DOI 10.1038/s41598-021-87748-0↗
  6. A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer. Co-author DOI 10.1097/md.0000000000026052↗
  7. A case of gastric wall implantation caused by EUS-FNA 22 months after pancreatic cancer resection. Co-author DOI 10.4103/eus.eus_58_17↗
  8. ARHGEF15 overexpression worsens the prognosis in patients with pancreatic ductal adenocarcinoma through enhancing the motility and proliferative activity of th… Co-author DOI 10.1186/s12943-016-0516-4↗
  9. Functional p38 MAPK identified by biomarker profiling of pancreatic cancer restrains growth through JNK inhibition and correlates with improved survival. First author DOI 10.1158/1078-0432.ccr-13-2823↗
  10. Evaluation of endoscopic cytological diagnosis of unresectable pancreatic cancer prior to and after the introduction of endoscopic ultrasound-guided fine-needl… Co-author DOI 10.3892/mco.2014.277↗
  11. Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. Co-author DOI 10.1158/1078-0432.ccr-12-1215↗
  12. Accuracy of differential diagnosis for pancreatic cancer is improved in the combination of RCAS1 and CEA measurements and cytology in pancreatic juice. Co-author DOI 10.1007/s00795-010-0511-6↗
  13. GATA6 activates Wnt signaling in pancreatic cancer by negatively regulating the Wnt antagonist Dickkopf-1. Co-author DOI 10.1371/journal.pone.0022129↗

Closest collaborators

The 25 strongest of 56 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yoshinobu Okabe · 9 shared papers, 2011–2024 · strength 0.91
  2. Jun Akiba · 6 shared papers, 2011–2023 · strength 0.58
  3. Takuji Torimura · 3 shared papers, 2018–2024 · strength 0.37
  4. Toru Hisaka · 2 shared papers, 2022–2024 · strength 0.31
  5. Hirohisa Yano · 4 shared papers, 2011–2022 · strength 0.29
  6. Takahiko Sakaue · 2 shared papers, 2021–2024 · strength 0.29
  7. Tomoyuki Ushijima · 3 shared papers, 2014–2021 · strength 0.24
  8. Yorihiko Takase · 1 shared paper, 2023 · strength 0.20
  9. Kenji Notohara · 2 shared papers, 2021–2022 · strength 0.19
  10. Noriyoshi Fukushima · 2 shared papers, 2021–2022 · strength 0.19
  11. Motohiro Kojima · 2 shared papers, 2021–2022 · strength 0.19
  12. Kenichi Hirabayashi · 2 shared papers, 2021–2022 · strength 0.19
  13. Toru Furukawa · 2 shared papers, 2021–2022 · strength 0.19
  14. Yusuke Ishida · 4 shared papers, 2011–2018 · strength 0.19
  15. Hironori Koga · 1 shared paper, 2024 · strength 0.17
  16. Takumi Kawaguchi · 1 shared paper, 2024 · strength 0.17
  17. Tõru Nakamura · 1 shared paper, 2024 · strength 0.17
  18. Keisuke Miwa · 1 shared paper, 2021 · strength 0.12
  19. Masaru Fukahori · 1 shared paper, 2021 · strength 0.12
  20. Atsushi Kanno · 1 shared paper, 2022 · strength 0.10
  21. Kensuke Kubota · 1 shared paper, 2022 · strength 0.10
  22. Shigeyuki Kawa · 1 shared paper, 2022 · strength 0.10
  23. Eisuke Iwasaki · 1 shared paper, 2022 · strength 0.10
  24. Itaru Naitoh · 1 shared paper, 2022 · strength 0.10
  25. Tsukasa Ikeura · 1 shared paper, 2022 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.